Morepen Laboratories has received USFDA approval for Montelukast Sodium, a bulk drug which is used in treatment of asthma and respiratory disorders. The drug market is estimated at Rs 2000 crore (approximately $ 300 million) US market for Montelukast. The drug Montelukast global market is estimated at about Rs 13000 crore (Approximately US $ 2 billion) out of which US market alone is Rs 2,000 crore. The patent for Montelukast has expired in all the market worldwide. In US the product got expired in 2012 and subsequently process patent expired in 2014.
Company Profile : Morepen Laboratories Ltd
Leave a Reply